AI is trained to spot warning signs in blood tests
Published On Dec 19, 2024, 7:05 PM
New developments in artificial intelligence (AI) are showing promise for early detection of ovarian cancer through advanced blood tests that analyze nanoparticle responses. A team at Memorial Sloan Kettering is training AI algorithms to decode complex data patterns from blood samples, offering higher accuracy than existing cancer biomarkers with the potential to triage gynecological diseases. In addition, AI is streamlining blood tests for other infections, like pneumonia, significantly reducing the time and cost of testing. Despite being in early stages, these technologies could revolutionize diagnostic practices in oncology and infectious diseases.
Stock Forecasts
KARS
Positive
The technological advancements in AI-driven diagnostics, particularly for cancer detection and infectious diseases, present significant investment opportunities in biotech and healthcare sectors. Companies specializing in these technologies, like Karius, may see increased demand for their services as hospitals look to improve efficiency and patient outcomes. Investors should pay attention to emerging biotech firms focusing on machine learning applications in diagnostics.